Loading stock…

LeMaitre Vascular, Inc. (LMAT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

LeMaitre Vascular, Inc.

LMATMarket cap $1.81BPrice $79.0

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

LeMaitre Vascular makes surgical devices and implants used to treat peripheral vascular disease, selling into a niche market too small for medical giants to bother with. That gap has let them dominate specialty tools like grafts, catheters, and stents for over 30 years.

In Bastion Portfolios?

52W Return-8%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+16%8

Revenue Forecast

Rev CAGR (1y)+11%6

Rev CAGR (3y)+9%7

Rev CAGR (5y)+10%7

Earnings Forecast

EPS Growth Y+1+14%7

EPS Growth Y+2+11%7

EPS Growth Y+3+12%7

Quality

Margins

EBIT Margin28%9

Net Income Margin25%8

Free Cash Flow Margin28%9

Debt

Net Debt/EBITDA-2.110

Efficiency

ROE17%7

ROA11%9

Earnings Stability88

GEAR+VERY STRONG90

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)263

P/E Ratio (Forward 3y)223

P/BV4.34

EV Multiples

EV/EBITDA Fwd193

EV/EBIT Fwd223

Yield

Free Cash Flow Yield4.1%6

Dividend Yield1.3%4

Momentum

Short term

1 month return-2%7

3 month return-25%1

YTD return-2%4

Mid term

Price vs 52wHigh67%3

1 year return-8%4

Long term

3 year return+41%5

5 year return+52%6

Risk Shield

Price Risk

Beta0.58

Volatility46%4

Free Cash Flow

Free Cash Flow Margin28%9

Free Cash Flow Yield4.1%6

Quality

ROCE13%7

Earnings Stability88

Net Debt/EBITDA-2.110

02Growth

Is it actually growing, and how fast?

LMATLeMaitre Vascular

Revenue FY25$250M

GROWTH RATING↗

STRONG68 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+9%7

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+14%7

EPS growth, FY27E+11%7

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 68% of companies worldwide.

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 9%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 12%/yr vs revenue 9%/yr).

WATCH

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 9%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return-25%1

YTD return-2%4

MID & LONG-TERM▾SCORE

% of 52-week high67%3

1-year return-8%4

3-year return+41%5

5-year return+52%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-2%).

WATCH

Average long-term results. Multi-year returns are middling (+41% over three years and +52% over five), roughly average for the market.

Returns sit at the market level so far this year (-2%).

WEAKNESSES

It's down 8% over the past year, now 33% below its 52-week high. That is a touch behind the market.

The stock is underperforming over three months (-25%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on LeMaitre Vascular, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

LMATLeMaitre Vascular

Revenue FY25$250M

GROWTH RATING↗

STRONG68 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+9%7

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+14%7

EPS growth, FY27E+11%7

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 68% of companies worldwide.

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 9%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 12%/yr vs revenue 9%/yr).

WATCH

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 9%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return-25%1

YTD return-2%4

MID & LONG-TERM▾SCORE

% of 52-week high67%3

1-year return-8%4

3-year return+41%5

5-year return+52%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-2%).

WATCH

Average long-term results. Multi-year returns are middling (+41% over three years and +52% over five), roughly average for the market.

Returns sit at the market level so far this year (-2%).

WEAKNESSES

It's down 8% over the past year, now 33% below its 52-week high. That is a touch behind the market.

The stock is underperforming over three months (-25%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on LeMaitre Vascular, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community